MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
CRISPR Therapeutics AG Book Value 2011-2026 | CRSP
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value CRISPR Therapeutics AG
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.93 B | 1.88 B | 1.88 B | 2.4 B | 1.66 B | 939 M | 392 M | 188 M | 233 M | -29.1 M | -6.97 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.4 B | -29.1 M | 1.04 B |
Quarterly Book Value CRISPR Therapeutics AG
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.92 B | 1.71 B | 1.83 B | 1.93 B | 1.94 B | 1.98 B | 2.08 B | 1.88 B | 1.73 B | 1.82 B | 1.85 B | 1.88 B | 1.95 B | 2.09 B | 2.24 B | 2.4 B | 2.51 B | 2.6 B | 1.81 B | 1.66 B | 1.66 B | 1.66 B | 1.66 B | 939 M | 939 M | 939 M | 939 M | 392 M | 392 M | 392 M | 392 M | 188 M | 188 M | 188 M | 188 M | 233 M | 233 M | 233 M | 233 M | 35.4 M | 35.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.6 B | 35.4 M | 1.27 B |
Book Value of other stocks in the Biotechnology industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M |  Canada |
 |
MorphoSys AG
MOR
|
49 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
I-Mab
IMAB
|
5.63 B | - | - | $ 866 M |  China |
 |
ANI Pharmaceuticals
ANIP
|
429 M | $ 81.6 | -0.49 % | $ 1.58 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
253 M | - | - | $ 40.3 B | USA |
 |
Amgen
AMGN
|
91.8 B | $ 342.65 | -0.08 % | $ 184 B | USA |
 |
Adagene
ADAG
|
50.5 M | $ 2.75 | -5.5 % | $ 155 M | China |
 |
Aeglea BioTherapeutics
AGLE
|
518 M | - | - | $ 1.01 B | USA |
 |
Biophytis SA
BPTS
|
34.9 M | - | -13.47 % | $ 169 M |  France |
 |
Midatech Pharma plc
MTP
|
8.32 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.33 B | - | -1.52 % | $ 24.7 M | USA |
 |
Aytu BioScience
AYTU
|
124 M | $ 2.63 | 1.74 % | $ 16.5 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.17 | -2.76 % | $ 7.63 B |  Australia |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
PainReform Ltd.
PRFX
|
1.82 M | $ 0.68 | -4.45 % | $ 308 K |  Israel |
 |
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
AVROBIO
AVRO
|
94.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Aptose Biosciences
APTO
|
-4.54 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Biogen
BIIB
|
16.7 B | $ 178.24 | 1.2 % | $ 26 B | USA |
 |
Brickell Biotech
BBI
|
11.6 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Beam Therapeutics
BEAM
|
734 M | $ 27.94 | -4.61 % | $ 2.3 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
10.6 M | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-106 M | $ 225.36 | 0.63 % | $ 5 B |  Danmark |
 |
Athira Pharma
ATHA
|
44.8 M | - | - | $ 269 M | USA |
 |
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioNTech SE
BNTX
|
19.4 B | $ 114.18 | -2.22 % | $ 27.2 B | Germany |
 |
Burford Capital Limited
BUR
|
1.66 B | $ 9.67 | 0.16 % | $ 1.52 B | Britain |
 |
Arrowhead Pharmaceuticals
ARWR
|
1.39 B | $ 70.74 | 2.34 % | $ 9.46 B | USA |
 |
CASI Pharmaceuticals
CASI
|
108 M | $ 0.99 | -0.01 % | $ 135 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.2 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
5.36 M | - | -10.17 % | $ 12.2 K | USA |
 |
Catalyst Biosciences
CBIO
|
78.5 M | $ 9.63 | -5.08 % | $ 634 M | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
20.1 M | - | -9.72 % | $ 5.89 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
39.5 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Berkeley Lights
BLI
|
142 M | - | -7.31 % | $ 87 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
20.3 M | $ 4.05 | -1.22 % | $ 8.81 B | Israel |
 |
Amneal Pharmaceuticals
AMRX
|
3.5 B | $ 13.65 | -3.3 % | $ 4.22 B | USA |
 |
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
2.53 M | - | -74.18 % | $ 955 K | USA |
 |
Cerus Corporation
CERS
|
56.9 M | $ 2.32 | -0.22 % | $ 428 M | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | USA |